For research use only. Not for therapeutic Use.
SL-145 is a C-terminal heat shock protein 90 (HSP90) inhibitor. SL-145 elicits anti-tumor and anti-metastatic effects without triggering the heat shock response (HSR) due to its unconventional targeting of the C-terminal region. SL-145 simultaneously inhibits multiple oncogenic signaling pathways including AKT, MEK/ERK, and JAK2/STAT3 in vitro and in vivo.
KEYWORDS: SL-145 | Supplier | HSP90 inhibitor | SL145 | SL 145 | CAS [2051587-62-1] | Unfolded protein response (Non selective) | Hsp90 | Inhibitor | Enzymes | Heat shock protein 90 | Metastatic triple-negative breast cancer | TNBC | Antiangiogenic
| Catalog Number | I047693 |
| CAS Number | 2051587-62-1 |
| Molecular Formula | C28H29NO6 |
| Purity | ≥95% |
| IUPAC Name | [(6,7-dimethoxyquinolin-4-yl)-(5-methoxy-2,2-dimethylchromen-6-yl)methyl] cyclopropanecarboxylate |
| InChI | InChI=1S/C28H29NO6/c1-28(2)12-10-18-22(35-28)9-8-19(25(18)33-5)26(34-27(30)16-6-7-16)17-11-13-29-21-15-24(32-4)23(31-3)14-20(17)21/h8-16,26H,6-7H2,1-5H3 |
| SMILES | CC1(C=CC2=C(O1)C=CC(=C2OC)C(C3=C4C=C(C(=CC4=NC=C3)OC)OC)OC(=O)C5CC5)C |
| Reference | HS Kim et al. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors. Bioorg Med Chem. 2016 Nov 15;24(22):6082-6093. JY Kim et al. A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response. Oncogene. 2022 Jun;41(23):3289-3297. |
